ArticleNature communications2026
Elimination of myotonia improves myopathy in a muscleblind-like knockout model of myotonic dystrophy.
Matthew T Sipple, Sakura A Hamazaki, Vanessa Todorow, Lily A Cisco, Katherine M Lupia, Christina S Heil, Peter Meinke, Charles A Thornton, John D Lueck
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors.
Sakura A HamazakiDepartment of Biology, University of Rochester, Rochester, NY, USA.
Vanessa TodorowYale University, New Haven, CT, USA.
Lily A CiscoDepartment of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Katherine M LupiaDepartment of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Charles A ThorntonDepartment of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Funding
University of Rochester Mentoring Environment: Nurturing Training Opportunities in Research (UR-MENTOR)T32GM007356 · NIGMS · UNIVERSITY OF ROCHESTER · PI O'BANION, M. KERRY · 1985 to 2023
$15.1MTraining Program in Oral ScienceT90DE021985 · NIDCR · UNIVERSITY OF ROCHESTER · PI OVITT, CATHERINE, YULE, DAVID I · 2011 to 2021
$5.6MTraining in Wellness and Resiliency at the University of Rochester Medical Center and College of Arts, Sciences & EngineeringT32GM135134 · NIGMS · UNIVERSITY OF ROCHESTER · PI Jeffrey J Hayes, Lynne E Maquat · 2020 to 2026
$2.9MMechanism of Skeletal Muscle Calcium Dysregulation in Myotonic DystrophyR01AR079424 · NIAMS · UNIVERSITY OF ROCHESTER · PI John D. Lueck · 2022 to 2026
$2.3MGenetic and pharmacologic elimination of myotonia from myotonic dystrophy type 1F31AR082284 · NIAMS · UNIVERSITY OF ROCHESTER · PI SIPPLE, MATTHEW THOMAS · 2023 to 2023
$48kDeutsche Forschungsgemeinschaft (German Research Foundation) 470092532NIAMS NIH HHS F31 AR082284NIAMS NIH HHS R01 AR079424NIDCR NIH HHS T90 DE021985NIGMS NIH HHS T32 GM007356NIGMS NIH HHS T32 GM135134U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) F31AR082284U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR079424U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) T90DE021985U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007356U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM135134
6 · The paper itselfAbstract
A cardinal sign of myotonic dystrophy type 1 (DM1) is myotonia, slow muscle relaxation after voluntary contraction. Myotonia results from mis-regulated splicing of chloride channel 1 (ClC-1), leading to loss of channel function and runs of involuntary action potentials in muscle fibers. Preceding the onset of weakness, myotonia is often the first symptom of DM1, and thus this raises the possibility that muscle hyperexcitability contributes to the subsequent weakness and myopathy. Here, we show that genomic deletion of ClC-1 exon 7a (E7a), a cryptic exon abnormally regulated in DM1, completely rescues of ClC-1 function and yields permanent elimination of myotonia in the muscleblind-like 1 (Mbnl1) knockout mouse model of DM1. The restoration of normal excitability results in normalization of muscle force generation, correction of fiber-type distribution, and improvement of muscle histology. E7a deletion also partially corrects the muscle transcriptome, including changes of differential gene expression and alternative splicing. These results indicate that E7a inclusion is a lynchpin splice event that contributes to myotonic myopathy, and support myotonia reduction as a therapeutic objective in DM1.
Indexed as
Chloride ChannelsMyotoniaMyotonic DystrophyRNA-Binding ProteinsAlternative SplicingAnimalsDisease Models, AnimalDNA-Binding ProteinsExonsFemaleHumansMaleMiceMice, KnockoutMuscle Fibers, SkeletalMuscle, SkeletalChloride ChannelsCLC-1 channelDNA-Binding ProteinsMbnl1 protein, mouseRNA-Binding Proteins
Identifiers
PMID42420272
PMCPMC13478325
What Socratic holds
Textmetadata
Read underepoch 390